ArticleAntimicrobial agents and chemotherapy2017
Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Anti-Sense Antibiotic Agents as Treatment for Bacterial Infections.Surgical infectionsPooled it
- Kinetics, thermodynamics, and mechanisms of PMO interactions from computational molecular modeling.Molecular therapy. Nucleic acids · 2026Article
- A systematic identification of resistance determinants to antisense antibiotics suggests adaptation strategies dependent on the delivery peptide.Nature communications · 2026Article
- Oligonucleotide genetics forbioRxiv : the preprint server for biology · 2026Article
- Polysorbates' effects on molecular and thermodynamic properties of phosphorodiamidate morpholino oligonucleotides' structures.Molecular therapy. Nucleic acids · 2026Article
- Developing antisense oligomer biotics "asobiotics" as precision antibacterials: designs, strategies, and considerations for future success.FEMS microbiology reviews · 2026Review
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
- Shelf-life extension of lettuce using cell-penetrating peptide-peptide nucleic acid conjugates targetingCurrent research in food science · 2026Article
- Article
- An antisense peptide-conjugated peptide nucleic acid (PPNA) for peptidoglycan recycling inhibition reduces AmpC hyperproduction and β-lactam resistance inMicrobiology spectrum · 2025Article
- ASOBIOTICS 2024: an interdisciplinary symposium on antisense-based programmable RNA antibiotics.RNA (New York, N.Y.) · 2025Article
- Antisense phosphorodiamidate morpholino oligomers retain activity inFrontiers in microbiology · 2025Article
- Chemical strategies for antisense antibiotics.Chemical Society reviews · 2024Review
- Identifying Cell-Penetrating Peptides for Effectively Delivering Antimicrobial Molecules intoAntibiotics (Basel, Switzerland) · 2024Article
- Sequence specificity defines the effectiveness of PPMOs targetingAntimicrobial agents and chemotherapy · 2023Article
- Antisense Therapy for Infectious Diseases.Cells · 2023Review
- Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics.Molecular therapy. Nucleic acids · 2023Article
- Evaluation ofMicroorganisms · 2023Article
- INRI-seq enables global cell-free analysis of translation initiation and off-target effects of antisense inhibitors.Nucleic acids research · 2022Article
- RNA-based therapeutics to treat human fungal infections.Trends in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
James J HowardDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Carolyn R SturgeDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Dina A MoustafaDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Seth M DalyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kimberly R Marshall-BattyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Christina F FelderDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Danniel ZamoraDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Marium Yabe-GillDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Maria Labandeira-ReyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Stacey M BaileySarepta Therapeutics, Cambridge, Massachusetts, USA.
Michael WongSarepta Therapeutics, Cambridge, Massachusetts, USA.
Joanna B GoldbergDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Bruce L GellerDepartment of Microbiology, Oregon State University, Corvallis, Oregon, USA.
David E GreenbergDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA david.greenberg@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USEmory University · USHarvard University · USOregon State University · USSarepta Therapeutics (United States) · US
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7MCircumventing Antibiotic Resistance with Novel Gene-Silencing TherapeuticsR33AI111753 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GELLER, BRUCE L, GREENBERG, DAVID ELIHU · 2016 to 2018
$1.4MGene silencing therapeutics for chronic infections in cystic fibrosisR33AI105980 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GREENBERG, DAVID ELIHU · 2015 to 2017
$1.1MGene silencing therapeutics for chronic infections in cystic fibrosisR21AI105980 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GREENBERG, DAVID ELIHU · 2013 to 2014
$416kCircumventing Antibiotic Resistance with Novel Gene-Silencing TherapeuticsR21AI111753 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GELLER, BRUCE L, GREENBERG, DAVID ELIHU · 2014 to 2015
$415kNCI NIH HHS P30 CA142543NIAID NIH HHS R21 AI105980NIAID NIH HHS R21 AI111753NIAID NIH HHS R33 AI105980NIAID NIH HHS R33 AI111753
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression Regulation, BacterialAmidohydrolasesAnimalsAnti-Bacterial AgentsBiofilmsFatty Acid Synthase, Type IIFemaleHumansMiceMice, Inbred BALB CMicrobial Sensitivity TestsMolecular Targeted TherapyMorpholinosOligonucleotides, AntisensePeptidesPseudomonas aeruginosaAmidohydrolasesAnti-Bacterial AgentsFatty Acid Synthase, Type IILpxC deacetylase, PseudomonasMorpholinosOligonucleotides, AntisensePeptidesRibosomal Proteinsantibiotic resistanceantimicrobial agentsantisenseexperimental therapeuticsphosphorodiamidate morpholino oligomerPPMOPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.